Plain-English translation of NCT03850574 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a clinical trial testing a new medication called for patients with acute myeloid leukemia (AML) or similar blood cancers that have not responded to earlier treatments or have come back after treatment. The trial is studying whether the medication is safe, how well it works, and what doses work best — either as a single treatment or combined with other approved medications. The goal is to find out if this new approach can help patients whose cancer has become resistant to standard care.
Patients with relapsed or refractory acute myeloid leukemia have few good treatment options, and many do not survive long after their cancer returns or stops responding to chemotherapy. Researchers developed this medication to target leukemia cells in a new way, and this trial will test whether it can offer patients a meaningful new option.
You likely qualify if…
You likely don't qualify if…
You would visit a cancer center regularly to receive the medication as a pill taken by mouth, typically once or twice daily. The trial has different phases: early phases test safety at different dose levels, while later phases focus on effectiveness in larger groups of patients. You will have frequent blood tests and clinic visits to monitor how well the treatment is working and to watch for side effects. The full duration depends on which part of the trial you join and how you respond, but you would continue treatment as long as the medication is helping and side effects remain manageable.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States